Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories
NASHVILLE, Tenn., March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers. The HE 800 C combines ergonomic features and consistent performance in a compact size to meet the evolving needs of fertility clinics, biorepositories and clinical laboratories.
"With the HE 800 C, we are delivering an unmatched cryogenic storage solution that balances high-capacity preservation with a practical and user-friendly, space-efficient design," said Jerrell Shelton, CEO, Cryoport. "With the ability to store over 22,000 ½cc straws, the HE 800 C offers ultra-cold, high-density storage while optimizing workflow, enabling clinics and laboratories to maximize their available space without compromising the security of these critical life sciences materials."
Building on the trusted reputation of the HE Series, the HE 800 C provides ultra-low temperature storage at -190°C, ensuring the integrity of sensitive biological materials. The HE 800 C is compatible with SUC-1 inventory management systems, which enables easy identification and retrieval of samples to streamline sample organization and retrieval. Its superior ergonomic design makes loading and retrieving samples more accessible, reducing strain on laboratory personnel.
"Reliability, efficiency and access are key in cryogenic storage, and the HE 800 C is designed to excel in these areas," added Mike Duich, President and CEO, MVE Biological Solutions. "The HE 800 C provides enhanced sample safety while making retrieval and organization more intuitive and efficient, ultimately allowing medical researchers and clinicians to focus on their work with confidence."
To learn more about the HE 800 C, please visit https://mvebio.com/our-products/life-science-freezers/he800c or reach out to [email protected].
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to MVE Biological Solutions' High-Efficiency 800 C freezer, including its potential impact on revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoports-mve-biological-solutions-expands-high-efficiency-cryogenic-freezer-series-with-answer-to-evolving-needs-of-fertility-clinics-biorepositories-and-clinical-laboratories-302399517.html
SOURCE Cryoport, Inc.